MedTrace Logo

Dietary Supplement (Beta-Glucans) in Allergic Patients Undergoing Subcutaneous Immunotherapy.

NCT06448585 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2025-08-29

No results posted yet for this study

Summary

The present study will attempt to determine if the dietary supplement, based on a synergistic combination of β-glucans and Saccharomyces cerevisiae yeast enriched with Zinc and Selenium, can improve the immune response in allergic patients diagnosed with rhinitis or rhinoconjunctivitis, with or without controlled asthma, who are undergoing subcutaneous polymerized 100 immunotherapy with a rapid initiation protocol. It will also attempt to determine if the dietary supplement in combination with DAO enzyme could improve the immunological response to immunotherapy.

Conditions

  • Rhinitis
  • Allergic Rhinoconjunctivitis
  • Rhinoconjunctivitis
  • Controlled Asthma
  • Uncontrolled Asthma

Interventions

DRUG

Specific immunotherapy (SIT) treatment

Treatment with subcutaneous polymerized 100 specific immunotherapy (SIT) in its initiation phase with rapid (clustered) dosing, where the highest allergen concentration (0.2 + 0.3 mL) is administered directly, with an interval of 30 to 45 minutes between injections, in allergology consultations of the SES.

DIETARY_SUPPLEMENT

Dietary Supplement: ABB C1

Ingredients: betaglucanos, levadura Saccharomyces cerevisiae, selenio y zinc. 1 sachet/day; contains 3 grams

DIETARY_SUPPLEMENT

Mini-tablets with pork extract

Mini-tablets with pork extract containing the diamine oxidase enzyme (3 mini-tablets/day)

Sponsors & Collaborators

  • Gala Servicios Clinicos S.L.

    lead OTHER

Principal Investigators

  • Juan Antonio Carrillo, Medicine · Universidad de Extremadura

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-29
Primary Completion
2024-05-29
Completion
2024-12-10

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06448585 on ClinicalTrials.gov